Background {#Sec1}
==========

Multidrug resistant tuberculosis (MDR-TB) is a major concern hampering global tuberculosis control efforts \[[@CR1], [@CR2]\]. According to new estimates from World Health Organization (WHO), there were around 0.48 million new cases of MDR-TB cases, and approximately 0.19 million deaths from MDR-TB worldwide in 2014 (WHO, 2015). Only behind India, China has the second burden of MDR-TB globally, with 52, 000 prevalent MDR-TB cases annually (WHO, 2015). A recent national survey of drug-resistant tuberculosis in China revealed that 5.7% of new TB cases and 25.6% of previously treated cases were MDR-TB, respectively, which were higher than the global average rates \[[@CR3]\]. Given its high rate of treatment failure, the epidemic of MDR-TB constitutes a serious public health problem in China \[[@CR3], [@CR4]\].

Pyrazinamide (PZA) is one of cornerstone first-line anti-tuberculosis agents that is also commonly used as essential component in the therapeutic treatment of MDR-TB \[[@CR5], [@CR6]\]. As the prodrug, PZA requires conversion into its active form pyrazinoic acid (POA) by the enzyme pyrazinamidase (PZase). PZase is encoded by the 561-nucleotide *pncA* gene. Loss of PZase activity cause by genetic mutations in the *pncA* gene is the main mechanism of resistance to PZA in *M. tuberculosis* \[[@CR6]\]. Several recent literatures have reported that several PZA-resistant *M. tuberculosis* isolates harbored the mutations in the promoter of *pncA* gene, indicating these alternations may result in PZA resistance by influencing the expression of *pncA* \[[@CR7]--[@CR9]\]. In addition to *pncA*, another gene named *rpsA*, which encodes the 30S ribosomal protein S1, has been demonstrated to confer PZA resistance by structural alternation of POA binding \[[@CR10]\]. To date, the contribution of the *rpsA* mutations conferring PZA resistance is controversial, which requires more experimental evidences to elucidate the role of *rpsA* as a PZA resistance mechanism \[[@CR8]\].

Chongqing is the largest municipality in the southwestern China \[[@CR11]\]. Due to the underdeveloped setting, Chongqing is considered as a hotspot for both TB and MDR-TB in China \[[@CR12]\]. However, limited data is available for the prevalence and molecular characteristics of PZA resistance in *M. tuberculosis* isolates, especially MDR-TB. In this study, our main goal was to investigate the prevalence of PZA resistance among MDR-TB isolates collected in Chongqing municipality. We also sought to analyze the mutant profiles of MDR-TB isolates conferring PZA resistance in this area.

Methods {#Sec2}
=======

Patient enrollment {#Sec3}
------------------

All smear-positive tuberculosis patients who were registered at local TB dispensaries between November 2014 and February 2016 were enrolled in this study. Information was obtained from patient's medical record. Two sputum samples were obtained from each smear-positive patient for culturing in the county-level laboratories. After 4--8 weeks of incubation, cultures with growing colonies on Löwenstein-Jensen (L-J) medium were sent to the Chongqing Tuberculosis Control Institute for further drug susceptibility testing. Re-treated cases were defined as patients having previously received more than one month of anti-TB treatment.

Drug susceptibility testing {#Sec4}
---------------------------

Drug susceptibility testing (DST) was performed with the proportional method recommended by WHO \[[@CR3], [@CR13]\]. The concentrations of drugs in L-J medium were as follows: isoniazid (INH), 0.2 μg/ml; rifampicin (RIF), 40 μg/ml; ethambutol (EMB), 2 μg/ml; streptomycin (SM), 4 μg/ml; ofloxacin (OFLX), 2 μg/ml; kanamycin (KAN), 30 μg/ml; amikacin (AMK), 30 μg/ml; capromycin (CAP), 40 μg/ml; and protionamide (PTO), 40 μg/ml and p-aminosalicylic acid (PAS) 1 μg/ml \[[@CR14]\]. A strain was declared resistant to an antimicrobial agent when the growth rate exceeded 1% compared with the control. In addition, PZA susceptibility testing was determined with a Bactec MGIT 960 system according to the manufacturer's instructions. The critical concentration of PZA in the liquid medium was 100 μg/ml \[[@CR8]\]. The MDR-TB strains were defined as those resistant to both isoniazid and rifampicin. In addition, XDR-TB was defined as MDR-TB resistant to any member of the quinolone family and at least one of the remaining second-line anti-TB injectable drugs \[[@CR15]\].

DNA extraction and amplification {#Sec5}
--------------------------------

Genomic DNA was extracted from freshly cultured bacteria as previously described \[[@CR16]\]. Briefly, the harvested bacteria from the surface of L-J medium were suspended in 500 μl Tris-EDTA (TE) buffer and heated in a 95 °C water bath for 30 min. The crude DNA was used as template for amplification. The fragments of *pncA* and *rpsA* were amplified with the following primers: *pncA*-F 5′-AACAGTTCATCCCGGTTC-3′ and *pncA*-R 5′-GCGTCATGGACCCTATATC-3′; *rpsA*-F 5′-CGGAGCAACCCAACAATA-3′ and *rpsA*-R 5′-GTGGACAGCAACGACTTC-3′, respectively \[[@CR17]\]. The 50 μL PCR mixture was prepared as follows: 25 μl 2 × GoldStar MasterMix (CWBio, Beijing, China), 5 μL of DNA template, and 0.2 μM of each primer set. PCR parameters for amplification were 5 min at 94 °C followed by 35 cycles of 94 °C for 1 min, 58 °C for 1 min, 72 °C for 1 min and a final extension of 72 °C for 5 min. PCR products were sent to Tsingke company for sequencing. All sequence data were aligned with *pncA* and *rpsA* of reference strain H37Rv (ATCC) using BioEdit (version 7.1.3.0) software.

Quantitative reverse transcription PCR (QRT-PCR) {#Sec6}
------------------------------------------------

Bacteria were harvested from L-J medium after inoculation for 4 weeks. The total RNA was isolated following a standard Trizol RNA extraction protocol supplied by Invitrogen (Invitrogen, Life Technologies, USA) \[[@CR18]\]. Followed by treatment with DNaseI (Invitrogen, Life Technologies, USA), the reverse transcription was carried out using SuperScriptIII RT kit (Invitrogen, Life Technologies, USA). The relative expression level of *pncA* gene was detected by QRT-PCR in a 20 μl system containing 10 μL of 2 × UltraSYBR Mixture (CWBio, Beijing, China), 2 μL of cDNA template, and 0.2 μM of each primer set (pncA-QF 5′-GAAGCGGCGGACTACCATC-3′ and pncA-QR 5′-AGTGGCGTGCCGTTCTCG-3′). PolyA was set as the internal control in respective PCR experiments \[[@CR18]\].

Data analysis {#Sec7}
-------------

Chi square test was used to evaluate the associations among multiple categorical variables, and the statistical results were summarized with odds ratios (ORs) with 95% confidence intervals (CIs). All calculations were performed in SPSS 13.0 (SPSS Inc., USA). Differences with a *P* value less than 0.05 were declared statistically significant.

Results {#Sec8}
=======

Demographic characteristics and drug susceptibility profiles {#Sec9}
------------------------------------------------------------

A total of 133 (10.8%) of 1236 clinical isolates were identified as MDR-TB, including 38 (28.6%) pre-XDR and 17 (12.8%) XDR. Overall, 80 (60.2%) strains were isolated from male patients and 53 (39.8%) from female patients. The average age of the patients was 46.6 years (range 19--76 years). In addition, 36.8% of isolates were from new cases, and 63.2% from re-treated cases. Out of the 133 MDR isolates tested, 97 (72.9%) were resistant to SM, 40 (30.1%) to EMB, 52 (39.1%) to OFLX, 20 (15.0%) to KAN, 16 (12.0%) to AMK, 11 (8.3%) to CAP and 15 (11.3%) to PAS (Table [1](#Tab1){ref-type="table"}).Table 1Risk factor associate with PZA resistance among 133 MDR^a^ isolatesCharacteristicsNo. (%) of isolates\
(*n* = 133)No. (%) of isolatesOR\
(95% CI)*P* valuePZA^R^\
(*n* = 83)PZA^S^\
(*n* = 50)Sex Male80 (60.2)47 (56.6)33 (66.0)0.67 (0.33--1.39)0.29 Female53 (39.8)36 (43.4)17 (34.0)1.0 (Ref.)--Age group  \< 3031 (23.3)18 (21.7)13 (26.0)1.0 (Ref.)-- 30--5980 (60.2)55 (66.3)25 (50.0)1.59 (0.68--3.74)0.29  ≥ 6022 (16.5)10 (12.0)12 (24.0)0.60 (0.20--1.81)0.36Treatment history New case49 (36.8)22 (26.5)27 (54.0)1.00 (Ref.)-- Re-treated84 (63.2)61 (73.5)23 (46.0)3.26 (1.55--6.82)\<0.01Resistance to: SM97 (72.9)69 (83.1)28 (56.0)3.87 (1.74--8.63)\<0.01 EMB40 (30.1)26 (31.3)14 (28.0)1.17 (0.54--2.54)0.69 OFLX52 (39.1)43 (51.8)9 (18.0)4.89 (2.11--11.35)\<0.01 KAN20 (15.0)19 (22.9)1 (2.0)14.58 (1.88--112.44)\<0.01 AMK16 (12.0)15 (18.1)1 (2.0)10.81 (1.38--84.58)0.01 CAP11 (8.3)10 (12.0)1 (2.0)6.71 (0.83--54.12)0.05 PAS15 (11.3)13 (15.7)2 (4.0)4.46 (0.96--20.65)0.04Pre-XDR^b^38 (28.6)30 (36.1)8 (16.0)2.97 (1.23--7.16)0.02XDR^c^17 (12.8)16 (19.3)1 (2.0)11.70 (1.50--91.22)\<0.01^a^MDR is defined as *Mycobacterium tuberculosis* strain resistant to at least isoniazid and rifampin^b^Pre-XDR is defined as MDR strain additionally resistant to either ofloxacin or kanamycin, but not both^c^XDR is defined as *Mycobacterium tuberculosis* strain resistant to isoniazid, rifampin, ofloxacin and kanamycin

Factors associated with PZA resistance {#Sec10}
--------------------------------------

As shown in Table [1](#Tab1){ref-type="table"}, 83 (62.4%) isolates were determined as PZA-resistant by MGIT, while the other 50 (37.6%) were susceptible to PZA. In regard to the distribution of MDR-TB cases treatment history, the percentage of re-treated MDR-TB patients in the PZA-resistant group was significantly higher than in the PZA-susceptible group (odd ratio (OR) \[95% confidence interval (CI): 3.26\[1.55--6.82\], *P* \< 0.01). In contrast, our data revealed no statistically significant difference between the PZA-resistant and PZA-susceptible group in gender and age (*P* \> 0.05).

We further analyzed the resistance profiles of other drugs among PZA-resistant and PZA-susceptible *M. tuberculosis* strains. Statistical analysis revealed that SM- (83.1% vs. 56.0%, *P* \< 0.01), OFLX- (51.8% vs. 18.0%, *P* \< 0.01), KAN- (22.9% vs. 2.0%, *P* \< 0.01), AMK- (18.1% vs. 2.0%, *P* = 0.01), CAP-resistance (12.0% vs. 2.0%, *P* = 0.05), pre-XDR (36.1% vs. 16.0%, *P* \< 0.02) and XDR (19.3% vs. 2.0%, *P* \< 0.01) were more frequently observed among PZA-resistant isolates compared with PZA-susceptible isolates, while no difference was identified between EMB-resistant and EMB-susceptible strains (31.3% vs. 28.0%, *P* = 0.69) (Table [1](#Tab1){ref-type="table"}).

Mutations in the *pncA* and *rpsA* gene {#Sec11}
---------------------------------------

A total of 73 out of 83 (88.0%) MDR strains harbored a mutation located in the *pncA* gene, including 55 (75.3%, 55/73) of single nucleotide substitutions and 18 (24.7%, 18/73) of frameshift mutation. As summarized in Table [2](#Tab2){ref-type="table"}, we observed great mutant diversity in *pncA* gene, and there were 48 different mutant types conferring PZA resistance among MDR strains in Chongqing. The most prevalent mutation associated with PZA resistance was found in codon 132 of *pncA* (12.3%, 9/73), resulting in the amino aicd substitution of Gly to Asp. As the second affected codon, five isolates had a mutation in codon 62 (6.8%, 5/73). Notably, the third frequent mutation was the nucleotide substitution from A to G at position −11 in the promoter region of *pncA*, accounting for 5.4% of mutant isolates. We also found that 4 PZA-susceptible isolates carried a genetic mutation in *pncA*, including 2 strains in codon 62, one in codon 67 and one in codon 154 (Table [3](#Tab3){ref-type="table"}). In addition, no genetic mutation associated with PZA resistance was found in the *rpsA* gene in this study.Table 2Mutations of PZA-resistant MDR-TB isolates within *pncA*LocusPosition of nucleotideNucleotide substitutionPosition of amino acidAmino acid substitutionNo. of isolates*pncA*−11TAT → TGT−4Tyr → Cys42ATG → ACG1Met → Thr120GTC → GGC7Val → Gly224GAC → GAG8Asp → Glu128CAG → TAG10Gln → Stop135GAC → GCC12Asp → Ala237TTC → GTC13Phe → Val140TGC → CGC14Cys → Arg240TGC → CGC14Cys → Arg194TTC → GTC32Phe → Val1123TAC → TAG41Tyr → Stop1146GAC → GCC49Asp → Gly1146GAC → GCC49Asp → Ala2151CAC → TAC51His → Tyr1151CAC → CGC51His → Arg1152CAC → CCC51His → Pro1170CAC → CGC57His → Arg1185CCG → CTG62Pro → Leu5206CCG → CTG69Pro → Leu1213CAT → CAG71His → Gln1226ACT → CCT76Thr → Pro3232GGC → AGC78Gly → Asp1245CAT → CGT82His → Arg1286AAG → CAG96Lys → Gln1307TAC → CAC103Tyr → His1309TAC → TAG103Tyr → Stop1319GAA → AAA107Glu → Lys1395GGT → GAT132Gly → Asp9425ACG → ATG142Thr → Met1437GCG → GTG146Ala → Val1464GTG → GGG155Val → Gly1488GTG → GCG163Val → Ala1515CTG → CCG172Leu → Pro252insertion of GC1130insertion of C1136deletion of G2139insertion of CA1232insertion of C1243insertion of T1288insertion of A1341deletion of ACGCC1342deletion of GCCAC2376deletion of GATGAGGTC1392insertion of G1392insertion of GG1393insertion of GGT1408insertion of CA1408insertion of A2Total73 Table 3Mutations in PZA-susceptible MDR-TB isolates within *pncA* geneLocusPosition of nucleotideNucleotide substitutionPosition of amino acidAmino acid substitutionNo. of isolates*pncA*184CCG → ACG62Pro → Thr1185CCG → CAG62Pro → Gln1200TCG → TGG67Ser → Trp1461AGG → AAG154Arg → Lys1Total4

We analyzed the performance of *pncA* mutations for predicting PZA susceptibility. When setting the phenotypic PZA susceptibility as a gold standard, we found that detection of mutations in *pncA* gene exhibited a sensitivity of 88.0% (95% CI, 80.9%--95.0%) and a specificity of 92.0% (95% CI, 84.5%--99.5%) (Table [4](#Tab4){ref-type="table"}).Table 4Performance of *pncA* mutations for predicting PZA susceptibilityMutation in *pncA*PZA susceptibility^a^TotalSensitivity\
(95% CI, %)Specificity\
(95% CI, %)PPV\
(95% CI, %)NPV\
(95% CI, %)RSYes7347788.0\
(80.9--95.0)92.0\
(84.5--99.5)94.8\
(89.8--99.8)82.1\
(72.1--92.2)No104656Total8350133^a^ *R*, resistant, *S* susceptible, *PPV* positive predictive value, *NPV* negative predictive value, *CI* confidence interval

Loss of *pncA* expression due to promoter mutation {#Sec12}
--------------------------------------------------

We further explore whether the substitution at position −11 affected the expression level of *pncA*. As shown in Fig. [1](#Fig1){ref-type="fig"}, compared with reference strain H37Rv, the relative expression level of *pncA* in MDR87, MDR88, MDR114 and MDR126 carried the substitution at position −11 were 0.25 fold, 0.19 fold, 0.36 fold and 0.22 fold, respectively. Statistical analysis revealed that the *pncA* expression of strains harboring promoter mutation at position −11 was significantly lower than that of H37Rv (*P* \< 0.01).Fig. 1Relative expression level of *pncA* gene in 4 *M. tuberculosis* isolates with mutation in the position −11 of promoter region

Discussion {#Sec13}
==========

PZA plays a unique role in the treatment for MDR-TB in both first- and second-line regimens \[[@CR19], [@CR20]\]. The prevalence of PZA among MDR-TB thus is a determining factor for initiation of PZA in the therapy regimens for these refractory patients \[[@CR21]\]. Here, our data demonstrated that 62.4% of MDR-TB exhibited resistance against PZA in Chongqing, which was similar to a recent literature from Beijing (57.7%) \[[@CR22]\], while higher than those from Zhejiang (43.1%) \[[@CR8]\], Shanghai (38.5%) \[[@CR23]\], United States (38.0%) \[[@CR19]\], and Thailand (49.0%) \[[@CR24]\]. The high prevalence of PZA resistance among MDR-TB patients from our report indicates that Chongqing is a hotspot of PZA resistance in China. In our study, more than 60% MDR patients received previous anti-TB therapy with PZA, which is significantly higher than the average national level (21.8%) \[[@CR3]\]. Hence, we speculate that the high proportion of PZA resistance may be contributed to the high rate of re-treated TB patients. The serious issue on PZA resistance highlights the diminished role of PZA in the treatment for MDR-TB in this setting with high MDR-TB burden. Prior to the use of PZA for treatment of MDR-TB cases, it is essential to perform in vitro susceptibility testing against PZA to formulate a suitable regimen \[[@CR21]\].

Another important finding from our observation was that we observed that there were high correlation between PZA resistance and several other drugs' resistance, including OFLX, second-line injectable drugs, and PAS. Similar to our findings, a recent report from Alame-Emane and colleagues has revealed that PZA resistance in *M. tuberculosis* arises after RIF and fluoroquinolone (FQ) resistance \[[@CR25]\]. Genetic mutations constitute the most important mechanism conferring drug resistance in *M. tuberculosis* \[[@CR20]\]. Exposure to bacterial species to antimicrobial agents, including RIF, FQ and the aminoglycosides, induces the production of oxygen radicals, thereby conferring high frequency mutagenesis \[[@CR25]--[@CR27]\]. Considering long duration of anti-TB treatment, we hypothesize that MDR bacteria will harbor more genetic mutations induced by prolonged exposure to these drugs, which may be responsible for the potential cross resistance between PZA and other drugs in our study.

In vitro susceptibility against PZA is essential for proper management of MDR-TB with regimen containing PZA \[[@CR21]\]. However, phenotypic DST for PZA is not routinely performed due to the requirement of harshly acidic environment \[[@CR17]\]. Molecular method based on detecting the mutations in *pncA* and *rpsA* serves as an alternative to predict the PZA susceptibility in *M. tuberculosis* \[[@CR9]\]. In this study, our data demonstrated that genetic alternations in *pncA* confer 88.0% of PZA resistance among MDR-TB in Chongqing. A number of studies have demonstrated a diverse prevalence of *pncA* mutation among PZA resistant isolates in different regions, ranging from 45.7% in Brazil \[[@CR28]\], 70.6% in Iran \[[@CR29]\], 75.0% in Thailand \[[@CR24]\], 78.0% in Zhejiang \[[@CR8]\], 84.6% in Southern China \[[@CR9]\], and 94.1% in Sweden \[[@CR30]\]. Hence, *pncA* mutations may differ from one geographic region to another. In addition, we found that *pncA* mutations exhibited great diversity, and the most frequent mutant type in codon 142 only accounted for approximate 12% of PZA resistant isolates, which was also different from reports from other regions \[[@CR8], [@CR9]\]. Given the diversity of *pncA* mutations within more than 500-bp long segment, DNA sequencing of the entire *pncA* is more effective for verification of PZA resistance rather than the routine methods by covering the mutant hotspots.

In addition, the third frequent mutation identified in this study was located at position −11 of the *pncA* promoter region. In line with our observation, numerous literatures have observed this mutant type in PZA-resistant *M. tuberculosis* isolates \[[@CR31], [@CR32]\]. We found that this substitution at position −11 was associated with low level of *pncA* expression, which was also consistent to the observation from Sheen et al. \[[@CR31]\]. The anti-TB activity of PZA depends on the transformation to POA by PZAse, which is encoded by *pncA* gene. The loss of *pncA* transcriptional level may result in the relative low PZAse activity, which is further associated with the phenotypic PZA resistance. Our results suggest that the promoter region of *pncA* is recommended to be included in the sequence analysis of *pncA* gene.

We acknowledge several limitations of this study. First, the small sample size is a major limitation of our report. And all the strains collected from one region also reduce their representativeness and thereby constrict the generalizability of findings. Further wider sampling will give more credence to this study. Second, although the primary data of this study suggest that loss of *pncA* expression caused by promoter mutation confers PZA resistance in MDR-TB isolates, we could give no biochemical or transgenic substantiation of this statement. Therefore, there is an urgent need to confirm our findings with more experimental evidences in the future. Third, the high diversity of *pncA* mutations in MTB-TB isolates from Chongqing underscores previous findings that there is no clear hotspot for *pncA* mutations \[[@CR30]\], and several novel mutations in *pncA* gene were found for first time among PZA-resistant isolates. Despite being highly correlated with the loss of PZA susceptibility, further experiments will be carried out to clarify the potential contributions of these mutations to PZA resistance. Nevertheless, our report firstly described the molecular characteristics of PZA resistance among MDR-TB isolates from Southern China, which provides important hints to diagnose PZA resistance and help guide therapy with PZA for MDR-TB patients in this region with high MDR-TB burden.

Conclusion {#Sec14}
==========

In conclusion, our data have demonstrated that the analysis of the *pncA* gene rather than *rpsA* gene provides rapid and accurate information regarding PZA susceptibility for MDR-TB isolates in Chongqing. In addition, loss of *pncA* expression caused by promoter mutation confers PZA resistance in MDR-TB isolates. Considering the high degree of diversity of *pncA* gene mutations, DNA sequencing of the entire *pncA* is more effective for verification of PZA resistance rather than the routine methods by covering the mutant hotspots. The high prevalence of PZA resistance among MDR highlights the diminished role of PZA in the treatment for MDR-TB in this setting with high TB burden.
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